A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients
Status unconfirmed
Conditions studied: Pan-cancer
In brief
The purpose of this study is to determine the benefit of Cellworks Singula™ and Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.
Key facts
- Study ID
- NCT05308784
- Run by
- Avera McKennan Hospital & University Health Center
- People needed
- 730
- Starts
- 2022-01-01
- Expected to finish
- 2025-12-31
- Last updated by the study team
- 2023-07-19
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Avera McKennan — Sioux Falls, South Dakota, United States (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.